Compare · NVO vs SGMT
NVO vs SGMT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sagimet Biosciences Inc. (SGMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SGMT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 340.0x SGMT ($633.8M).
- Over the past year, NVO is down 12.1% and SGMT is up 45.5% - SGMT leads by 57.6 points.
- SGMT has been more active in the news (11 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for SGMT).
- Company
- Novo Nordisk A/S
- Sagimet Biosciences Inc.
- Price
- $48.65+3.65%
- $10.29+0.83%
- Market cap
- $215.46B
- $633.8M
- 1M return
- -2.08%
- +38.12%
- 1Y return
- -12.07%
- +45.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SGMT
- Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
- Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Kemble George exercised 350,987 units of Series A Common Stock at a strike of $6.36 and sold $3,591,580 worth of Series A Common Stock (350,987 units at $10.23) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Sagimet Biosciences Inc.
- SEC Form 8-K filed by Sagimet Biosciences Inc.
- Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
- Director Kemble George exercised 20,206 units of Series A Common Stock at a strike of $6.36 and sold $201,147 worth of Series A Common Stock (20,206 units at $9.95) as part of a pre-agreed trading plan (SEC Form 4)
- Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- SEC Form 10-Q filed by Sagimet Biosciences Inc.
- Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates